Context Therapeutics gets Nasdaq notice for failing $1 minimum bid price rule

• Context Therapeutics received a Nasdaq notice for failing to meet the $1 minimum bid price requirement for 30 consecutive business days.
• Shares remain listed for now, with an initial compliance window running through Jan. 25, 2027.
• Compliance requires a closing bid price of at least $1 for 10 consecutive business days, subject to Nasdaq discretion.
• Failure to regain compliance could trigger delisting proceedings, with a possible additional 180-day cure period if eligibility conditions are met.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Context Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-051399), on July 31, 2026, and is solely responsible for the information contained therein.